Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 12/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574005 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL671495 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL21226786 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL435130 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL29756947 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL3714541 | 0.79 | DAO (1.00) | DAORIPK1AURKAPARP1 | |
| SCHEMBL15528142 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL27984199 | 0.77 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL6421464 | 0.76 | DAO (0.61) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL22185856 | 0.76 | DAO (0.61) | DAORIPK1AURKAPARP1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2293778-B1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND MOMETASONE | INTERVET INT BV (NL) | 2013-09-18 | — | — | EP | claimed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | claimed |
| EP-2293778-A2 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | Intervet International B.V. (NL) | 2011-03-16 | — | — | EP | claimed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | claimed |
| WO-2009147144-A2 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL B.V. (NL) | 2009-12-10 | — | — | WO | claimed |
| CN-112824406-B | Enoxacin propenone derivative and preparation method and application thereof | 河南大学 | 2023-10-17 | — | — | CN | disclosed |
| CN-112824406-B | Enoxacin propenone derivative and preparation method and application thereof | 河南大学 | 2023-10-17 | — | — | CN | disclosed |
| CN-112824405-B | Acrylic ketone derivative of N-methyl enoxacin and preparation method and application thereof | 河南大学 | 2023-06-02 | — | — | CN | disclosed |
| CN-112824406-A | Enopropione derivative of enoxacin and preparation method and application thereof | 河南大学 | 2021-05-21 | — | — | CN | disclosed |
| CN-112824404-A | N-acetyl enoxacin acrylketone derivative and preparation method and application thereof | 河南大学 | 2021-05-21 | — | — | CN | disclosed |
| CN-112824404-A | N-acetyl enoxacin acrylketone derivative and preparation method and application thereof | 河南大学 | 2021-05-21 | — | — | CN | disclosed |
| CN-112824405-A | N-methylenoxacin acrylketone derivative and preparation method and application thereof | 河南大学 | 2021-05-21 | — | — | CN | disclosed |
| US-6362229-B1 | SYNERGISTIC MIXTURE WITH BACTERICIDES, FUNGICIDES | INFLUX, INC. | 2002-03-26 | — | — | US | disclosed |
| US-6326391-B1 | USING INDOLE COMPOUND | INFLUX, INC. | 2001-12-04 | — | — | US | disclosed |
| EP-1135132-A2 | INHIBITORS OF MULTIDRUG TRANSPORTERS | Influx, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6239141-B1 | ANTIBIOTIC | PFIZER INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2001015695-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001000209-A1 | METHODS OF USE OF FLUOROQUINOLONE COMPOUNDS AGAINST BACTERIA | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1057828-A2 | Trovafloxacin oral suspensions | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000032196-A2 | INHIBITORS OF MULTIDRUG TRANSPORTERS | INFLUX, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | DAO 1472/4885RIPK1 4834/4885AURKA 983/4885 |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | DAO 1472/4885RIPK1 4834/4885AURKA 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.